Acurx Pharmaceuticals (ACXP) Receivables (2023 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Receivables for 4 consecutive years, with $140278.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 248.88% year-over-year to $140278.0; the trailing twelve-month figure through Jun 2026 stood at $140278.0 (up 248.88% YoY), and the FY2025 full-year result was $48417.0, down 5.3% from the prior year.
• Receivables advanced to $140278.0 in Q2 2026 per ACXP's latest filing, from $56313.0 in the prior quarter.
• Across five years, Receivables topped out at $140278.0 in Q2 2026 and bottomed at $40208.0 in Q2 2025.
• Historically, Receivables has averaged $72690.0 across 4 years, with a median of $51127.0 in 2024.
• The sharpest annual moves came in 2024 and 2026: Receivables sank 60.42% in 2024, then jumped 248.88% in 2026.
• Over 4 years, Receivables stood at $129159.0 in 2023, then plunged by 60.42% to $51127.0 in 2024, then retreated by 5.3% to $48417.0 in 2025, then jumped by 189.73% to $140278.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $140278.0, $56313.0, and $48417.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.